Health Economics›Acute myeloid leukemia›First-line induction therapy older patients or "unfit" patients

First-line induction therapy older patients or "unfit" patients

Acute myeloid leukemia · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Azacitidine monotherapy Variant #01	FLT3	R 29 332	28d	—	9.8 mo	6	R 175 992 PFS proxy	7
7+3d and Sorafenib Variant #01	FLT3	R 17 786	7d	—	—	~1	~R 17 786 indirect	—

2 of 2 regimens shown